Bristol Myers Squibb (BMS) is highlighting results from a research study on circulating tumor DNA (ctDNA) liquid biopsy published April 28 in PLOS ONE.
BMS scientists demonstrated that Predicine's PredicineAtlas liquid biopsy next-generation sequencing (NGS) assay outperformed four other tests in detection sensitivity, specificity, accuracy, and reproducibility. The Precidine assay also proved capable of identifying gene deletion or copy number reductions in the study, Bristol Myers Squibb said.
